Back

Whole exome sequencing in patients with recurrent pericarditis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Acute and chronic pericarditis: how to best manage your patients Pericarditis ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Valentino Collini

University of Udine, Udine (Italy)

9 More presentations in this session

Presentation thumbnail
A novel risk-stratification model that predicts long-term clinical outcomes in patients with recurrent pericarditis
Doctor A. Kumar (Washington, DC, US)
Abstract Slides Video
Presentation thumbnail
Prognostic factors and etiological insights in constrictive pericarditis
Doctor L. Admella Severiano (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Short-pulse of systemic steroids in acute pericarditis: an alternative in refractory cases
Doctor A. Sanchez Arjona (Majadahonda, ES)
Abstract Slides Video
Presentation thumbnail
Increased adoption of IL-1 pathway inhibition and the steroid-sparing paradigm shift: temporal trends in recurrent pericarditis treatment from the RESONANCE patient registry
Doctor P. Cremer (Chicago, US)
Abstract Slides Video
Presentation thumbnail
Multi-year recurrent pericarditis disease duration in Italian patients: clinical outcomes after cessation of long-term IL-1 pathway inhibition provide insights for chronic management
Doctor M. Imazio (Udine, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Acute and chronic pericarditis: how to best manage your patients

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Idiopathic recurrent pericarditis in children and adults:clinical and diagnostic differences
thumbnail
Congress Presentation
A case report of recurrent pericarditis associated with NLRP12 gene variant in adulthood
thumbnail
Congress Presentation
Multi-year recurrent pericarditis disease duration in Italian patients: clinical outcomes after cessation of long-term IL-1 pathway inhibition provide insights for chronic management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources